68-5

70/120

atherosclerosis. Clin Chem, 2009; 55: 1801-1808. 5） Sakai S, Nakaseko C, Takeuchi M, et al: Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clin Chim Acta, 2012; 413: 1542-1548. 6) Kajiyama Y, Iwanuma Y, Tomita N, et al: Indication and Limitation of 3-field Lymph Node Dissection Surgery For Esophageal Cancer From Survival Anal-ysis. J Jpn Surg Assoc, 2007; 68: 795-804. (in Japanese) 7) Watanabe K, Suzuki H, Jiang M, et al: Soluble LR11 is a novel biomarker for vascular lesions late after Kawa-saki disease. Atherosclerosis, 2016; 246: 94-97. 8) Watanabe K, Suzuki H, Jiang M, et al: Soluble LR11 as a Novel Biomarker in Acute Kawasaki Disease. Circ J. 2021; CJ-20-1271. 9) Sobin LH, Gospodarowicz MK, Wittekind C, eds. Union for International Cancer Control (UICC) TMN Classi-fication of Malignant Tumours, 7th edition. New Jersey: Wiley- Blackwell, 2009.10) Japan Esophageal, S; Japanese Classification of Esoph-ageal Cancer, 11th edition: part I. Esophagus, 2017; 14: 1-36.11) Japan Esophageal, S; Japanese Classification of Esoph-ageal Cancer, 11th edition: part II and III. Esophagus, 2017; 6: 37-65.12) Jiang M, Bujo H, Ohwaki K, et al: Ang II-stimulated migration of vascular smooth muscle cells is depen-dent on LR11 in mice. J Clin Invest, 2008; 118: 2733-2746.13) Takahashi M, Bujo H, Jiang MZ, Noike H, Saito Y, Shirai K: Enhanced circulating soluble LR11 in patients with coronary organic stenosis. Atherosclerosis, 2010; 210: 581-584.14） Kawaguchi T, Ohwada C, Takeuchi M, et al: Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma. Leuk Lymphoma, 2014; 55: 2391-2394.15） Fujimura K, Ebinuma H, Fukamachi I, et al: Circu-lating LR11 is a novel soluble-receptor marker for early-stage clinical conditions in patients with non- Hodgkin’s lymphoma. Clin Chim Acta, 2014; 430: 48-54.16） Terai K, Jiang M, Tokuyama W, et al: Levels of soluble LR11/SorLA are highly increased in the bile of patients 520with biliary tract and pancreatic cancers. Clin Chim Acta, 2016; 457: 130-136.17） Tsuda T, Tahara E, Kajiyama G, Sakamoto H, Terada M, Sugimura T: High incidence of coamplification of list-1 and int-2 genes in human esophageal carci-nomas. Cancer Res, 1989; 49: 5505-5508.18） Tahara E： A Proposal from Molecular Biology to Clinic: Implication for Gastroinetstinal Cancer. Jpn J Gastoen-terol Surg, 1994; 27: 735-742. (in Japanese)19） Iwasaki Y, Arai K, Katayanagi S, et al: Biomarkers for neoplasmas in digestive organs. Gan To Kagaku Ryoho, 2004; 31: 1015-1020. (in Japanese)20） Jares P, Fernandez PL, Campo E, et al: Prad-1 Cyclin D1 Gene Amplification Correlates with Messenger- Rna Overexpression and Tumor Progression in Human Laryngeal Carcinomas. Cancer Res, 1994; 54: 4813-4817. 21） Muller D, Millon R, Lidereau R, et al: Frequent Ampli-fication of 11q13 DNA Markers Is Associated with Lymph-Node Involvement in Human Head and Neck Squamous-Cell Carcinomas. Eur J Cancer B Oral Oncol, 1994; 30B: 113-120.22） Michalides R, van Veelen N, Hart A, Loftus B, Wientjens E, Balm A: Overexpression of cyclin D1 correlates with recurrence in a group of forty-seven operable squamous cell carcinomas of the head and neck. Cancer Res, 1995; 55: 975-978.23） Shinozaki H, Ozawa S, Ando N, et al: Cyclin D1 ampli-fication as a new predictive classification for squamous cell carcinoma of the esophagus, adding gene informa-tion. Clin Cancer Res, 1996; 2: 1155-1161.24） Sakai S, Nakaseko C, Takeuchi M, et al: Circulating soluble LR11/SorLA levels are highly increased and ameliorated by chemotherapy in acute leukemias. Clin Chim Acta, 2012; 413: 1542-1548.25) Sugita Y, Ohwada C, Kawaguchi T, et al: Prognostic impact of serum soluble LR11 in newly diagnosed diffuse large B-cell lymphoma: A multicenter prospec-tive analysis. Clin Chim Acta, 2016; 463: 47-52.26） Yao T, Nomura R, Kajiyama Y: Aggressive Superficial Esophageal Carcinoma-Its Clinicopathological Charac-teristics. Stomach and Intestine, 2013; 48: 1245-1252. (in Japanese)